Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal Sells 2,650 Shares

Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Lloyd Mitchell Segal sold 2,650 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $4.79, for a total value of $12,693.50. Following the sale, the chief executive officer now owns 89,166 shares of the company’s stock, valued at approximately $427,105.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lloyd Mitchell Segal also recently made the following trade(s):

• On Wednesday, March 27th, Lloyd Mitchell Segal sold 2,650 shares of Repare Therapeutics stock. The stock was sold at an average price of $4.63, for a total value of $12,269.50.

Repare Therapeutics Stock Up 3.1 %

Shares of RPTX stock opened at $4.67 on Thursday. Repare Therapeutics Inc. has a fifty-two week low of $3.08 and a fifty-two week high of $13.85. The stock has a market cap of $172.79 million, a P/E ratio of -2.09 and a beta of 0.62. The business has a fifty day simple moving average of $6.33 and a 200-day simple moving average of $6.60.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.11). Repare Therapeutics had a negative net margin of 183.43% and a negative return on equity of 39.82%. The firm had revenue of $13.05 million during the quarter, compared to analysts’ expectations of $15.92 million. On average, sell-side analysts anticipate that Repare Therapeutics Inc. will post -2.74 earnings per share for the current year.

Analyst Ratings Changes

RPTX has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a research note on Wednesday, February 21st. Bloom Burton cut Repare Therapeutics from a “buy” rating to an “accumulate” rating in a research report on Tuesday, February 13th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Barclays PLC purchased a new position in shares of Repare Therapeutics in the second quarter valued at $36,000. Deutsche Bank AG acquired a new position in Repare Therapeutics in the 4th quarter valued at about $40,000. UBS Group AG raised its stake in Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after purchasing an additional 739 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Repare Therapeutics by 185.8% in the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after buying an additional 1,977 shares during the last quarter. Finally, SRS Capital Advisors Inc. purchased a new position in shares of Repare Therapeutics during the first quarter valued at approximately $49,000. Hedge funds and other institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.